Business Context and Reporting Period
Lifeward Ltd. (formerly ReWalk Robotics Ltd.) is a medical device company incorporated in Israel, trading on the Nasdaq Capital Market under the symbol LFWD. The company designs and commercializes rehabilitation solutions, including the ReWalk exoskeletons for spinal cord injury, AlterG Anti-Gravity systems, and MyoCycle FES cycles. This summary covers the fiscal year ended December 31, 2024.
Key operational developments in 2024 included the rebranding to Lifeward, the acquisition of AlterG (completed in August 2023), and the closure of U.S. facilities in Fremont, California, and Queens, New York, to streamline operations.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $25.7 million | $13.9 million |
| Gross Profit | $8.2 million | $4.5 million |
| Gross Margin | 32% | 32% |
| Net Loss | $(28.9) million | $(22.1) million |
| Operating Loss | $(29.3) million | $(23.6) million |
| Cash and Cash Equivalents (Year-End) | $6.7 million | $28.1 million |
| Net Cash Used in Operating Activities | $(21.7) million | $(20.7) million |
| Accumulated Deficit | $(264.8) million | $(235.9) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 85% year-over-year, driven by the full-year impact of the AlterG acquisition ($7.9 million contribution) and increased ReWalk sales due to Medicare coverage expansion.
- Impairment Charges: The company recorded a non-cash impairment charge of $9.8 million in 2024 related to acquired intangible assets (customer relationships, technology, and trademarks) due to lower-than-expected financial performance. No such charge was recorded in 2023.
- Operating Expenses: General and Administrative (G&A) expenses decreased 48% to $5.2 million, primarily due to a $2.6 million remeasurement gain on the AlterG earn-out liability and reduced M&A costs. Conversely, Sales and Marketing expenses increased 29% to $17.9 million due to higher headcount and promotional activities.
- Liquidity: Cash reserves declined significantly from $28.1 million to $6.7 million, reflecting high operating cash burn and the lack of significant financing activity during the year (excluding a subsequent January 2025 offering).
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
Management and auditors have concluded there is substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to recurring losses, negative operating cash flows, and an accumulated deficit of $264.8 million. Continued operations depend on securing additional financing.
Recent Capital Raise
In January 2025 (subsequent to the reporting period), the company completed a registered direct offering raising approximately $5.0 million to fund commercial efforts and working capital.
Strategic Outlook
- Medicare Reimbursement: The company is aggressively targeting the Medicare customer base following the establishment of a lump-sum purchase fee schedule ($91,032) for personal exoskeletons effective April 2024.
- Streamlining: The company expects to save approximately $3 million in operating expenses and improve gross margins by 2 percentage points following the closure of U.S. facilities and the transition of AlterG manufacturing to a contract manufacturer (Cirtronics).
- Product Pipeline: The ReWalk 7 next-generation exoskeleton submission is pending FDA review. The ReBoot soft exo-suit for stroke patients remains on hold pending further commercial evaluation.
Key Risks
- Geopolitical Instability: Operations and manufacturing (ReWalk) are located in Israel. Ongoing conflicts in the region pose risks to supply chains, employee availability (military reserve duty), and facility safety.
- Reimbursement Uncertainty: Revenue relies heavily on third-party payors. While Medicare coverage is established, private insurer coverage remains inconsistent and case-by-case.
- Equity Compensation: The company's 2014 Incentive Compensation Plan expired in August 2024, and a new plan has not yet been approved by shareholders, potentially impacting the ability to retain key personnel.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.7 million year-end cash balance plus the $5.0 million raised in January 2025 to cover the ~$21.7 million annual operating cash burn.
- Medicare Claims Volume: Monitor the actual volume of approved Medicare claims and collections to validate the revenue growth assumptions tied to the new reimbursement code (K1007).
- Equity Plan Approval: Confirm shareholder approval status for a new equity incentive plan to assess retention risks for executive management.
- Geopolitical Impact: Assess any disruptions to the Sanmina manufacturing facility in Israel or the new Cirtronics facility in New Hampshire due to regional conflicts.
- Intangible Asset Valuation: Review the assumptions used in the $9.8 million impairment charge to understand the revised revenue forecasts for the AlterG business.